Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synthetic MR AB's ROE % for the quarter that ended in Mar. 2026 was -20.86%. Synthetic MR AB's PB Ratio for the quarter that ended in Mar. 2026 was 11.04.
Synthetic MR AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1.89%.
Synthetic MR AB ROE % Adjusted to Book Value Related Terms
Synthetic MR AB ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Synthetic MR AB's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synthetic MR AB ROE % Adjusted to Book Value Chart
LTS:0G79 vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison
For the Health Information Services subindustry, Synthetic MR AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -1.89% mean?
Synthetic MR AB (LTS:0G79) has a ROE % Adjusted to Book Value of -1.89% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Synthetic MR AB and its competitors.
Is Synthetic MR AB's ROE % Adjusted to Book Value too high?
Synthetic MR AB's current ROE % Adjusted to Book Value is -1.89%. Overall, Synthetic MR AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's ROE % Adjusted to Book Value compare to VEEV and BTSG?
Synthetic MR AB's ROE % Adjusted to Book Value of -1.89% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Synthetic MR AB and its competitors. Synthetic MR AB's current ROE % Adjusted to Book Value is -1.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Synthetic MR AB (LTS:0G79) has a current ROE % Adjusted to Book Value of -1.89%. The stock's GF Value™ is kr122.54, compared to a current price of kr16.23 — trading 86.8% below its estimated fair value. The current ROE % Adjusted to Book Value is -1.89%. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Synthetic MR AB (LTS:0G79), the current ROE % Adjusted to Book Value is -1.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (LTS:0G79) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of kr16.23 is trading 86.8% below its estimated GF Value™ of kr122.54.
Key valuation signals for LTS:0G79:
ROE % Adjusted to Book Value: -1.89%
GF Value™: kr122.54 vs. price of kr16.23 (86.8% below fair value)
No single metric tells the full story. See the LTS:0G79 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for LTS:0G79
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G79 has been successfully added to your 
